Ten-eleven translocation 1 (TET1) gene is a potential target of miR-21-5p in human colorectal cancer

Ya Wen Cheng, Chia Jung Chou, Pei Ming Yang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

DNA 5-methylcytosine (5-mC) methylation, a key epigenetic mark, is critical for biological and pathological processes. Aberrant DNA methylation occurs in all tumor types and correlates with tumor suppressor gene silencing. DNA methylation is thought to be very stable, and active DNA demethylation remains a long-standing enigma. Recently, the ten-eleven translocation (TET) family of oxygenases are found to oxidize 5-mC to 5-hydroxymethylcytosine (5-hmC), which is prerequisite for active DNA demethylation. Both TET1 expression and global 5-hmC content are significantly reduced in colorectal cancer (CRC), the top leading cause of cancer-related death in the world. However, the involving molecular mechanisms are still unclear. The oncogenic microRNA (miRNA) miR-21-5p has recently identified as a diagnostic and prognostic biomarker in CRC. In this study, TET1 was predicted as a novel target of miR-21-5p by using a web-based predictive software starBase v2.0. We found that the 3′-UTR region of TET1 gene contains a miR-21-5p-binding site. Examination of tumor tissues from CRC patients found that loss of TET1 was associated with the progression of CRC to advance stages. In addition, negative correlation of miR-21-5p and TET1 expression was also observed. Transfection of the synthetic miR-21-5p mimic or inhibitor into the colorectal cancer cells could inhibit or increase the TET1-3′-UTR luciferase activity, respectively. Our results demonstrate that TET1 is a potential target of miR-21-5p in CRC.

Original languageEnglish
Pages (from-to)76-81
Number of pages6
JournalSurgical Oncology
Volume27
Issue number1
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Colorectal Neoplasms
5-Methylcytosine
Genes
3' Untranslated Regions
DNA Methylation
DNA
Biological Phenomena
Neoplasms
Oxygenases
Gene Silencing
Pathologic Processes
Tumor Suppressor Genes
Luciferases
MicroRNAs
Epigenomics
Methylation
Transfection
Software
Biomarkers
Binding Sites

Keywords

  • Colorectal cancer
  • Epigenetics
  • microRNA
  • miR-21
  • TET1

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Ten-eleven translocation 1 (TET1) gene is a potential target of miR-21-5p in human colorectal cancer. / Cheng, Ya Wen; Chou, Chia Jung; Yang, Pei Ming.

In: Surgical Oncology, Vol. 27, No. 1, 01.03.2018, p. 76-81.

Research output: Contribution to journalArticle

@article{40b3251b8e134f4aabba99b07394232f,
title = "Ten-eleven translocation 1 (TET1) gene is a potential target of miR-21-5p in human colorectal cancer",
abstract = "DNA 5-methylcytosine (5-mC) methylation, a key epigenetic mark, is critical for biological and pathological processes. Aberrant DNA methylation occurs in all tumor types and correlates with tumor suppressor gene silencing. DNA methylation is thought to be very stable, and active DNA demethylation remains a long-standing enigma. Recently, the ten-eleven translocation (TET) family of oxygenases are found to oxidize 5-mC to 5-hydroxymethylcytosine (5-hmC), which is prerequisite for active DNA demethylation. Both TET1 expression and global 5-hmC content are significantly reduced in colorectal cancer (CRC), the top leading cause of cancer-related death in the world. However, the involving molecular mechanisms are still unclear. The oncogenic microRNA (miRNA) miR-21-5p has recently identified as a diagnostic and prognostic biomarker in CRC. In this study, TET1 was predicted as a novel target of miR-21-5p by using a web-based predictive software starBase v2.0. We found that the 3′-UTR region of TET1 gene contains a miR-21-5p-binding site. Examination of tumor tissues from CRC patients found that loss of TET1 was associated with the progression of CRC to advance stages. In addition, negative correlation of miR-21-5p and TET1 expression was also observed. Transfection of the synthetic miR-21-5p mimic or inhibitor into the colorectal cancer cells could inhibit or increase the TET1-3′-UTR luciferase activity, respectively. Our results demonstrate that TET1 is a potential target of miR-21-5p in CRC.",
keywords = "Colorectal cancer, Epigenetics, microRNA, miR-21, TET1",
author = "Cheng, {Ya Wen} and Chou, {Chia Jung} and Yang, {Pei Ming}",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.suronc.2017.12.004",
language = "English",
volume = "27",
pages = "76--81",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Ten-eleven translocation 1 (TET1) gene is a potential target of miR-21-5p in human colorectal cancer

AU - Cheng, Ya Wen

AU - Chou, Chia Jung

AU - Yang, Pei Ming

PY - 2018/3/1

Y1 - 2018/3/1

N2 - DNA 5-methylcytosine (5-mC) methylation, a key epigenetic mark, is critical for biological and pathological processes. Aberrant DNA methylation occurs in all tumor types and correlates with tumor suppressor gene silencing. DNA methylation is thought to be very stable, and active DNA demethylation remains a long-standing enigma. Recently, the ten-eleven translocation (TET) family of oxygenases are found to oxidize 5-mC to 5-hydroxymethylcytosine (5-hmC), which is prerequisite for active DNA demethylation. Both TET1 expression and global 5-hmC content are significantly reduced in colorectal cancer (CRC), the top leading cause of cancer-related death in the world. However, the involving molecular mechanisms are still unclear. The oncogenic microRNA (miRNA) miR-21-5p has recently identified as a diagnostic and prognostic biomarker in CRC. In this study, TET1 was predicted as a novel target of miR-21-5p by using a web-based predictive software starBase v2.0. We found that the 3′-UTR region of TET1 gene contains a miR-21-5p-binding site. Examination of tumor tissues from CRC patients found that loss of TET1 was associated with the progression of CRC to advance stages. In addition, negative correlation of miR-21-5p and TET1 expression was also observed. Transfection of the synthetic miR-21-5p mimic or inhibitor into the colorectal cancer cells could inhibit or increase the TET1-3′-UTR luciferase activity, respectively. Our results demonstrate that TET1 is a potential target of miR-21-5p in CRC.

AB - DNA 5-methylcytosine (5-mC) methylation, a key epigenetic mark, is critical for biological and pathological processes. Aberrant DNA methylation occurs in all tumor types and correlates with tumor suppressor gene silencing. DNA methylation is thought to be very stable, and active DNA demethylation remains a long-standing enigma. Recently, the ten-eleven translocation (TET) family of oxygenases are found to oxidize 5-mC to 5-hydroxymethylcytosine (5-hmC), which is prerequisite for active DNA demethylation. Both TET1 expression and global 5-hmC content are significantly reduced in colorectal cancer (CRC), the top leading cause of cancer-related death in the world. However, the involving molecular mechanisms are still unclear. The oncogenic microRNA (miRNA) miR-21-5p has recently identified as a diagnostic and prognostic biomarker in CRC. In this study, TET1 was predicted as a novel target of miR-21-5p by using a web-based predictive software starBase v2.0. We found that the 3′-UTR region of TET1 gene contains a miR-21-5p-binding site. Examination of tumor tissues from CRC patients found that loss of TET1 was associated with the progression of CRC to advance stages. In addition, negative correlation of miR-21-5p and TET1 expression was also observed. Transfection of the synthetic miR-21-5p mimic or inhibitor into the colorectal cancer cells could inhibit or increase the TET1-3′-UTR luciferase activity, respectively. Our results demonstrate that TET1 is a potential target of miR-21-5p in CRC.

KW - Colorectal cancer

KW - Epigenetics

KW - microRNA

KW - miR-21

KW - TET1

UR - http://www.scopus.com/inward/record.url?scp=85040229360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040229360&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2017.12.004

DO - 10.1016/j.suronc.2017.12.004

M3 - Article

AN - SCOPUS:85040229360

VL - 27

SP - 76

EP - 81

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 1

ER -